Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...

As we previously reported, this August the European Commission granted approval for Celltrion’s STELARA biosimilar, STEQEYMA. Earlier this ...

Arthritis in the knees can be a debilitating condition that affects a person's mobility and quality of life. Find out about types of knee arthritis, signs to watch for and treatment options.

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Explore how the platelet-to-albumin ratio correlates with disease activity in early rheumatoid arthritis, potentially serving ...

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

MoonLake Immunotherapeutics (MLTX) announced that the first patients have been screened at U.S. trial sites in its global Phase 3 clinical ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

in patients with active psoriatic arthritis (PsA). PsA is a chronic, debilitating and progressive inflammatory condition that ...

At-risk individuals who progress to rheumatoid arthritis (RA) have a distinctive gut microbial composition. HealthDay News — At-risk individuals who progress to rheumatoid arthritis (RA) have a ...